Cision Announces Exclusive Platinum Sponsorship For PRSA 2019 International Conference

Cision Announces Exclusive Platinum Sponsorship For PRSA 2019 International Conference

Canada NewsWire

CHICAGO, Oct. 15, 2019 /CNW/ – Cision (NYSE: CISN), a leading global provider of earned media software and services, today announced it is the exclusive platinum sponsor of the PRSA 2019 International Conference. The conference, which takes place in San Diego from October 20 – 22, will bring together the leading minds in PR, communications and marketing. This year the theme is ‘INSPIRE, INNOVATE, ENGAGE, INFLUENCE’ and the conference will provide unparalleled information, strategies and tools for the new trends impacting the communications and PR industry.

As the exclusive platinum sponsor, Cision will co-host the Sunday night opening reception with PRSA San Diego, have an exhibit booth throughout the conference, and host a session with Jackson Family Wines about going beyond traditional PR.

“Cision was eager to partner with PRSA once again for their International Conference, as it continues to be an especially important event for the industry,” said Erik Huddleston, Cision’s President. “PRSA and Cision are both committed to the same goal – supporting PR and communications professionals. We look forward to seeing the range of insights and impact that this year’s conference brings.”

This year’s International Conference provides an unparalleled opportunity for communications professionals to enhance their knowledge and skills, navigate change and advance their careers. Truly international in scope and offering nearly twice the learning opportunities than ever before, the Conference includes experts from across the globe and more than 140 presentations by speakers representing a diverse range of industries and sectors.

The PRSA 2019 International Conference includes 10 keynote presentations from influential newsmakers such as journalists Bob Woodward and Laura Ling; Microsoft communications executive Frank X. Shaw; former President of Mexico Vicente Fox and former First Lady Marta Sahagún de Fox; panels of executives from global agencies, multinational corporations and branches of the military, as well as networking events and an expansive exhibition hall.

For more information about the PRSA 2019 International Conference, or to register, visit

About Cision
Cision Ltd (NYSE: CISN) is a leading global provider of earned media software and services to public relations and marketing communications professionals. Cision’s software allows users to identify key influencers, craft and distribute strategic content, and measure meaningful impact. Cision has over 4,000 employees with offices in 22 countries throughout the Americas, EMEA, and APAC. For more information about its award-winning products and services, including the Cision Communications Cloud®, visit and follow Cision on Twitter @Cision. 

About PRSA
The Public Relations Society of America (PRSA) is the nation’s leading professional organization serving the communications community. PRSA is the principal advocate for industry excellence and ethical conduct and provides members lifelong learning opportunities and leading-edge resources to enhance professional connections and support them at every stage of their career. With more than 30,000 members, PRSA is collectively represented in all 50 states by more than 110 Chapters and 14 Professional Interest Sections, and on nearly 375 college and university campuses through its student organization, the Public Relations Student Society of America (PRSSA). For more information, please visit

Cision Media Contact:
Rebecca Dersh 
PR Manager

PRSA Media Contact:
Rod Granger
(212) 460-0307


Cision logo. (PRNewsFoto/Cision)

Cision View original content to download multimedia:


View original content to download multimedia:

Bausch Health’s Ortho Dermatologics Business To Present Data At The Fall Clinical Dermatology Conference

Bausch Health’s Ortho Dermatologics Business To Present Data At The Fall Clinical Dermatology Conference

Canada NewsWire

18 Poster Presentations on Investigational and Existing Products

LAVAL, Quebec, Oct. 15, 2019 /CNW/ — Bausch Health Companies Inc. (NYSE/TSX: BHC) and its dermatology business, Ortho Dermatologics, one of the largest prescription dermatology health care businesses, today announced the presentation of 18 posters during the Fall Clinical Dermatology Conference in Las Vegas (Oct. 17-20, 2019). The presentations will feature analyses on ALTRENO® (tretinoin 0.05%) Lotion, BRYHALI® (halobetasol propionate 0.01%) Lotion, DUOBRII® (halobetasol propionate 0.01% and tazarotene 0.045%) Lotion and SILIQ® (brodalumab) injection, as well as a new data on the investigational drug IDP-123 (tazarotene 0.045%) Lotion. Please see below for warning about suicidal ideation and behavior with SILIQ.

“At this year’s Fall Clinical, new data will be presented across our psoriasis and acne portfolios, which have expanded significantly over the last year with the FDA approvals of DUOBRII, BRYHALI and ALTRENO,” said Bill Humphries, president, Ortho Dermatologics. “A total of 18 posters will be presented during the meeting. This includes data on our investigational acne treatment IDP-123, which is currently under review by the FDA with a PDUFA date of Dec. 22, 2019, as well as analyses that further demonstrate the clinical benefits of our current portfolio. Doing so allows us to help address the unmet needs of patients and educate physicians with new information that can help inform their treatment decisions.”

The complete list of all poster presentations that will include Ortho Dermatologics products and pipeline programs during the meeting is as follows.

ALTRENO® (tretinoin) Lotion, 0.05%

  • Bhatia et al. “A Randomized, Observer-blind, Split-face Study to Assess Compatibility of Facial Foundation Makeup with Tretinoin 0.05% Lotion and Skin Texture After Application”
  • Han et al. “Novel Tretinoin 0.05% Lotion for the Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris in an Asian Population”
  • St. Surin-Lord et al. “Acne-Related Quality of Life: Efficacy of a Novel Tretinoin 0.05% Lotion in Male and Female Patients with Moderate-to-Severe Disease”
  • Woolery-Lloyd et al. “Acne-Related Quality of Life: Correlation Between Acne Symptom Scores and Other Domains Following Treatment with Tretinoin 0.05% Lotion”

(halobetasol propionate) Lotion, 0.01%

  • Bhatia et al. “Halobetasol 0.01% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis of the Lower Extremities”

® (halobetasol propionate 0.01% and tazarotene 0.045%)

  • Alexis et al. “Efficacy, Safety, and Tolerability of a Halobetasol 0.01%/Tazarotene 0.045% Fixed Combination in the Treatment of Moderate-to-Severe Plaque Psoriasis in a Hispanic Population: Post Hoc Analysis of Two Phase 3 Randomized Controlled Trials”
  • Glick et al. “Efficacy of Halobetasol 0.01%/Tazarotene 0.045% (HP/TAZ) Fixed Combination in the Treatment of Moderate Plaque Psoriasis: Indirect Comparison Between Pooled Phase 3 Trials of HP/TAZ and Oral Treatment (Apremilast)
  • Gold et al. “Long-Term Management of Moderate-to-Severe Plaque Psoriasis: Maintenance of Treatment Success Following Cessation of Fixed Combination Halobetasol Propionate 0.01% And Tazarotene 0.045% (HP/TAZ) Lotion”
  • Lebwohl et al. “Efficacy, Safety, and Tolerabilty of a Halobetasol 0.01%/Tazarotene 0.045% Fixed Combination in the Treatment of Severe Plaque Psoriasis: Post Hoc Analysis of Two Phase 3 Randomized Controlled Trials”
  • Tanghetti et al. “Optimized Formulation for Topical Application of a Fixed Combination Halobetasol/Tazarotene Lotion Using Polymeric Emulsion Technology.”

SILIQ® (brodalumab) Injection

  • Armstrong et al. “Importance of Complete Skin Clearance on Quality of Life: Analysis of Three Phase 3 Studies”
  • Bhatia et al. “Maintenance and Improvement of Skin Clearance Response With Brodalumab Among Patients With Moderate-to-Severe Psoriasis”
  • Gottlieb et al. “Long-term Efficacy and Safety of Brodalumab in Patients With or Without History of Psoriatic Arthritis: Analysis of Two Phase 3 Psoriasis Studies”
  • Lebwohl et al. “Long-term Efficacy and Safety of Brodalumab in Patients With Psoriasis Who Did Not Respond to Prior Biologics”
  • Leonardi et al. “Long-term Efficacy and Safety of Brodalumab Through 120 Weeks and After Withdrawal and Retreatment”
  • Ehst et al. Long-term Efficacy and Safety of Brodalumab in Patients With Psoriasis Disease Duration ≥10 Years: Analysis of Two Phase 3 Studies”
  • Prussick et al. Patients With Psoriasis Treated With Brodalumab: A Pooled Post Hoc Analysis of a Marker of Liver Inflammation in Individuals With Potential Indicators of Early Nonalcoholic Fatty Liver Disease”

IDP-123 (tazarotene 0.045%) Lotion

  • Draelos et al. “Comparison of a novel tazarotene 0.045% lotion to tazarotene 0.1% cream: patient-reported outcomes from a phase 2 clinical trial”

About Ortho Dermatologics
Ortho Dermatologics is one of the largest prescription dermatology businesses dedicated to helping patients in the treatment of a range of therapeutic areas, including psoriasis, actinic keratosis, acne, atopic dermatitis and other dermatoses. The Ortho Dermatologics portfolio includes several leading acne, anti-fungal and corticosteroid-responsive dermatoses products. More information can be found at

About Bausch Health
Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global company whose mission is to improve people’s lives with our health care products. We develop, manufacture and market a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health. More information can be found at

What is the most important information I should know about SILIQ?

Suicidal thoughts or behavior: Some patients taking SILIQ have had suicidal thoughts or ended their own lives. This risk is higher if you have a history of suicidal thoughts or depression. It is not known if SILIQ causes these thoughts or actions. Get medical help right away if you or a family member notices that you have any of the following symptoms: new or worsening depression, anxiety, or mood problems; thoughts of suicide, dying, or hurting yourself; attempt to commit suicide, or acting on dangerous impulses; other unusual changes in your behavior or mood.

Your healthcare provider will give you a SILIQ patient/wallet card about symptoms that need medical attention right away. Carry the card with you during treatment with SILIQ and show it to all of your healthcare providers.

Please click here for full Prescribing Information for SILIQ, including Boxed Warning about suicidal ideation and behavior, and Medication Guide.

Please see full Prescribing Information for DUOBRII, BRYHALI and ALTRENO.

Forward-looking Statements
This news release may contain forward-looking statements, which may generally be identified by the use of the words “anticipates,” “expects,” “intends,” “plans,” “should,” “could,” “would,” “may,” “will,” “believes,” “estimates,” “potential,” “target,” or “continue” and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in the Company’s most recent annual or quarterly report and detailed from time to time in the Company’s other filings with the Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. In addition, certain material factors and assumptions have been applied in making these forward-looking statements, including that the risks and uncertainties outlined above will not cause actual results or events to differ materially from those described in these forward-looking statements. The Company believes that the material factors and assumptions reflected in these forward-looking statements are reasonable, but readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch Health undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.

ALTRENO, BRYHALI, DUOBRII and SILIQ are trademarks of Ortho Dermatologics’ affiliated entities.

© 2019
Ortho Dermatologics’ affiliated entities.


Investor Contact:

Media Contact:

Arthur Shannon

Lainie Keller

(514) 856-3855

(908) 927-1198

(877) 281-6642 (toll free)

(PRNewsfoto/Valeant Pharmaceuticals Interna)

Bausch Health logo (PRNewsfoto/Bausch Health Companies Inc.)

Cision View original content to download multimedia:

SOURCE Bausch Health Companies Inc.

View original content to download multimedia:

ZTE launches industry-first 5G+VDSL2 hybrid home gateway

ZTE launches industry-first 5G+VDSL2 hybrid home gateway

Canada NewsWire

SHENZHEN, China, Oct. 15, 2019 /CNW/ — ZTE Corporation (0763.HK / 000063.SZ), a major international provider of telecommunications, enterprise and consumer technology solutions for the Mobile Internet, today has released the industry’s first 5G+VDSL2 hybrid home gateway, the H339X, at Broadband World Forum 2019.


Supporting a number of access technologies, such as 5G, VDSL2, PON and Ethernet WAN, the device is designed to provide operators with multiple broadband evolution solutions and help them build super high-performance networks.

The H339X 5G+VDSL2 hybrid home gateway enables broadband access in various scenarios. In areas with legacy copper infrastructure, users can employ the H339X to overcome the bandwidth constraints of xDSL and achieve gigabit speeds from a combination of 5G and xDSL networks.

In areas where copper or fiber cables are inaccessible, the H339X allows users to access broadband services via 5G and enjoy the superior low-rate, low-latency network experience.

With an SFP cage that can house a GPON/XG-PON/XGS-PON module, the H339X allows the access network to smoothly upgrade from DSL to PON, thereby enabling operators to conduct deep fiber deployments. Moreover, the H339X supports 10GE Ethernet WAN access, making it possible to build a home network in SFU+router mode. The H339X can be reused in network upgrades to help operators reduce the cost of devices and operations.

On the user side, the H339X 5G+VDSL2 hybrid home gateway supports Wi-Fi 6 and 4×4 11ax@2.4GHz+4×4 11ax@5GHz MU-MIMO, providing physical rates of up to 3.6 Gbps, which is three times the speed of AC1200 home gateways. With its 10GE LAN port and 5G ultra high-bandwidth interface, the H339X is able to bring users an ultimate broadband experience.

Compliant with the EasyMesh standard, the H339X is compatible with devices of different vendors, so as to help operators roll out home network services and allow them to build a smart mesh Wi-Fi network.

In terms of hardware design, the H339X 5G+VDSL2 hybrid home gateway features an advanced antenna array so that the RF bands of 5G and Wi-Fi do not interfere with each other. The X shape of the H339X symbolizes a future of endless possibilities, echoing the product’s integration of multiple access technologies.

ZTE leads in the CPE field by virtue of its strong R&D capabilities and the widespread adoption of its products across global markets. In Q1 2019, ZTE ranked second in terms of the global market share of CPE devices, according to a data report of the research firm IHS Markit.

ZTE is a provider of advanced telecommunications systems, mobile devices, and enterprise technology solutions to consumers, carriers, companies and public sector customers. As part of ZTE’s strategy, the company is committed to providing customers with integrated end-to-end innovations to deliver excellence and value as the telecommunications and information technology sectors converge. Listed in the stock exchanges of Hong Kong and Shenzhen (H share stock code: 0763.HK / A share stock code: 000063.SZ), ZTE sells its products and services in more than 160 countries.

To date, ZTE has obtained 25 commercial 5G contracts in major 5G markets such as Europe, Asia Pacific, MEA, etc. ZTE commits 10 per cent of its annual revenue to research and development and has leadership roles in international standard-setting organizations. ZTE is committed to corporate social responsibility and is a member of the UN Global Compact.

Media Contacts:

Margaret Ma
ZTE Corporation
Tel: +86 755 26775189

Cision View original content to download multimedia:

SOURCE ZTE Corporation

View original content to download multimedia: